Hizentra (Immunoglobulin (Human))

Hizentra is a ready-to-use 20% liquid immunoglobulin (human) solution indicated for subcutaneous administration. It is used to treat primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP) in adult and pediatric patients two years of age and older. Hizentra provides consistent immune support by maintaining appropriate IgG levels in individuals with weakened immune systems. Patients looking to buy Hizentra benefit from its self-administered subcutaneous delivery, allowing greater independence and treatment flexibility. Hizentra prefilled syringes are designed for ease of use and consistent dosing, promoting patient adherence and reducing infusion preparation time.

Directions

Hizentra should be administered subcutaneously according to a physician’s instructions, with dosage tailored to each patient’s body weight, clinical response, and serum IgG levels. For patients with PI, maintenance therapy generally involves weekly administration. For those with CIDP, Hizentra may be used as a maintenance therapy following IVIg induction. Patients must be trained on proper infusion techniques before initiating home therapy. Hizentra prefilled syringes should be stored refrigerated or at room temperature, away from light, and used within the product’s expiration guidelines.

Ingredients

Each milliliter of Hizentra contains 0.2 g (20%) immunoglobulin (human), glycine as a stabilizer, and water for injection. It is free from preservatives, proline, sucrose, and polysorbates. The immunoglobulin is derived from pooled human plasma, screened and processed to minimize the risk of viral transmission.

Cautions

Patients with a history of thrombosis, renal dysfunction, or known risk factors for these conditions should use Hizentra with caution. Adequate hydration is recommended before infusion, and the product should be administered at the lowest effective dose and rate appropriate for the patient. Periodic monitoring of renal function, serum IgG levels, and infusion site tolerance is advised. Patients and caregivers should be informed about the signs of hypersensitivity, hemolysis, and aseptic meningitis. It is important to consider the Hizentra cost when planning long-term therapy, and patients may consult their healthcare provider or specialty pharmacy for pricing and assistance options.

Contraindications

Hizentra is contraindicated in individuals with a history of anaphylactic or severe systemic reactions to human immunoglobulin. It should not be used in patients with hyperprolinemia due to the absence of proline in the formulation. Hypersensitivity to any component of the product also warrants avoidance.

Side Effects

Common side effects of Hizentra may include:

• Injection site reactions (e.g., swelling, redness, itching)
• Headache
• Fatigue
• Nausea
• Diarrhea
• Back pain
• Fever
• Cough

Serious adverse reactions can include hypersensitivity reactions, thromboembolic events, aseptic meningitis syndrome, and renal dysfunction. Patients should report any unusual or persistent symptoms to their healthcare provider promptly.